Canada to receive 2m doses of AstraZeneca’s vaccine manufactured by Serum Institute of India
Topics: CANADA ASTRAZENECA INDIA
AstraZeneca has licensed the manufacture of its ChAdOx1 vaccine to the Serum Institute. The first 500,000 doses will be delivered to Canada in the coming weeks and will quickly be ready for distribution to the provinces and territories. The remaining 1.5 million doses will arrive by mid-May.
The 2 million doses secured through this agreement are in addition to the 20 million doses already secured through an earlier agreement with AstraZeneca. Health Canada’s authorization of the AstraZeneca vaccine allows the Government of Canada to advance its work with AstraZeneca to finalize delivery schedules for the 20 million doses.
The Government of Canada has signed agreements with the following companies to secure access to their COVID-19 vaccines and vaccine candidates:
• Pfizer, which will supply a minimum of 40 million doses and up to 76 million doses of its messenger RNA (mRNA) vaccine developed with BioNTech, BNT162b2. The Pfizer-BioNTech COVID-19 vaccine was approved by Health Canada on December 9, 2020. Canada will receive 4 million doses of the Pfizer-BioNTech COVID-19 vaccine before the end of March, and more than 1.5 million doses in the first half of April.
• Moderna, which will supply 44 million doses of its mRNA vaccine, mRNA-1273. The Moderna COVID-19 vaccine was approved on December 23, 2020. During the week of March 8, Canada is expecting more than 460,000 doses of the Moderna vaccine, and another 846,000 during the week of March 22. These deliveries mean we will have received over 2 million doses in the first quarter.
• AstraZeneca, which will supply 20 million doses of its viral vector vaccine, ChAdOx1. The AstraZeneca COVID-19 vaccine was approved on February 26, 2021.
• Verity Pharmaceuticals Canada Inc./Serum Institute of India (in collaboration with AstraZeneca Canada Inc.), which will supply 2 million doses of the ChAdOx1 viral vector vaccine. The Verity Pharmaceuticals Canada Inc./Serum Institute of India (in collaboration with AstraZeneca Canada Inc.) COVID-19 vaccine was approved on February 26, 2021.
• Medicago, which will supply up to 76 million doses of its virus-like particle vaccine candidate.
• Sanofi and GlaxoSmithKline, which will supply up to 72 million doses of their protein subunit vaccine candidate.
• Johnson & Johnson, which will supply up to 38 million doses of its viral vector vaccine candidate, Ad26.COV2.S.
• Novavax, which will supply up to 76 million doses of its protein subunit vaccine candidate, NVX-CoV2373. ■